Month: September 2026

These Relevant Opportunities Are Valued in the Hundreds of Millions of Dollars

Newport Beach, CA, Sept. 18, 2026 (GLOBE NEWSWIRE) — Bimergen Energy Corporation (NYSE American: BESS), a developer, owner, and operator of utility-scale and distributed battery energy storage systems, today announced that its wholly owned subsidiary, Emergen Energy, LLC, has completed its System for Award Management (SAM.gov) registration and received its Commercial and Government Entity (CAGE) code 23R51. Emergen’s registration is active for “All Awards,” establishing the registration foundation to compete for federal contracts and pursue eligible federal assistance opportunities, subject to individual solicitation and program requirements.

The milestone supports Bimergen’s strategy of expanding the commercial reach of its energy storage development capabilities and building relationships that advance energy infrastructure projects. With an active federal registration, Emergen is positioned to pursue opportunities with government agencies and explore collaboration with prime contractors and other industry partners.

Assigned by the Defense Logistics Agency, the CAGE code identifies Emergen within federal procurement systems. The combination of active SAM.gov registration and CAGE code assignment completes a foundational step in the Company’s preparation to participate in the federal marketplace.

“Completing our federal registration is a meaningful step in expanding the opportunities available to Bimergen,” said Cole Johnson, Co-CEO of Bimergen Energy. “Our focus is on developing energy storage infrastructure that strengthens grid reliability and delivers flexible power when needed. We now have the registration foundation to pursue federal opportunities aligned with those capabilities and build relationships with government customers and industry partners.”

Bimergen’s growth strategy combines battery energy storage development with technology and capital partnerships designed to advance projects toward construction and operation. Participation in the federal marketplace offers a potential additional customer channel that complements the Company’s activities across U.S. power markets and its focus on reliable, resilient energy infrastructure.

“Our strategy is to convert development capabilities and strong partnerships into long-term shareholder value,” said Bob Brilon, Co-CEO of Bimergen Energy. “Active SAM.gov registration broadens the opportunities related to hundreds of millions of government contract dollars that we can pursue as we grow our business. We see federal contracting as a potential extension of our commercial strategy, with an emphasis on opportunities that fit our capabilities and support disciplined growth.”

The registration milestone builds on Bimergen’s ongoing efforts to expand its market presence, advance its energy storage portfolio, and establish partnerships that support project execution. The Company remains focused on matching development opportunities with the technology, capital, and operational resources needed to create lasting value.

About Bimergen Energy Corporation

Bimergen Energy Corporation (NYSE American: BESS) is a U.S.-based energy infrastructure developer, asset owner, and operator focused on utility-scale and distributed battery energy storage systems (BESS). The Company develops projects designed to enhance grid reliability, support renewable energy integration, and provide flexible energy solutions across key U.S. power markets. Bimergen works with technology providers and capital partners to advance projects through development, construction, and long-term operation.

For more information about Bimergen Energy, please visit www.bimergen.com.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. These statements include expectations regarding federal contracting and assistance opportunities, potential customer and market expansion, project development, strategic partnerships, and long-term shareholder value. Forward-looking statements may be identified by words such as “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “seek,” and similar expressions.

Forward-looking statements are based on Bimergen Energy Corporation’s current expectations and assumptions. Actual results may differ materially due to factors including procurement requirements and award decisions, competition, financing availability, regulatory approvals, project execution, and other risks described in the Company’s Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this announcement. Bimergen Energy Corporation undertakes no obligation to update these statements except as required by applicable law.

Media Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256 | 1-800-REDCHIP (733-2447)
BESS@redchip.com

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 18, 2026 (GLOBE NEWSWIRE) — CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a partnership with QIMA Life Sciences, a world leading preclinical dermatology CRO, to explore the potential of several of CDT’s assets in autoimmune skin diseases.

CDT plans to leverage QIMA’s unique access to human skin from both healthy donors and patients. The use of patient tissue offers the most clinically relevant data possible, providing rapid translation to clinic and providing potential license partners the highest level of confidence possible for clinical success.

Initial studies will be centred around tapinarof (VTAMA^®), a drug currently approved for plaque psoriasis and atopic dermatitis in the US and Japan. CDT has created a robust intellectual property portfolio around tapinarof, including solid form and method-of-use patents in combination with other known drugs. QIMA will explore the potential of these novel combinations in psoriatic patient skin, with the aim of working towards a second generation tapinarof product with increased efficacy and patient benefits. VTAMA^® is currently the number one branded topical treatment in the US, and CDT believe that developing a combination therapy could both expand, and extend, its market to further patient groups.

CDT also plans to investigate the potential of its proprietary tapinarof combinations in vitiligo, an autoimmune disease often associated with significant emotional and psychological distress for sufferers. Vitiligo is a common chronic autoimmune disorder affecting approximately 0.5%–2.0% of the global population, representing tens of millions of patients worldwide¹. The global vitiligo drug market was estimated at approximately US$2.6 billion in 2025 and is projected to reach US$6.6 billion by 2030². Current approved treatments often prove intolerable for many patients, especially pediatric patients, and re-pigmentation can take a considerable amount of time, demonstrating a significant unmet need for new therapies that are effective, yet tolerable. Working with human skin will allow CDT to explore the potential of these combinations in the most physiologically relevant setting possible.

For further information or to discuss potential partnership opportunities, please contact the Company at info@cdtequity.com.

About QIMA Life Sciences

QIMA Life Sciences is a contract research organization specializing in cellular and molecular pharmacology. It partners with pharmaceutical and biotechnology companies to advance research and accelerate drug development through tailored, science-driven solutions spanning early discovery through clinical development. By combining preclinical and clinical research and testing solutions with advanced AI-driven image analysis and digital data platforms, QIMA Life Sciences enables companies to generate the robust scientific evidence needed to bring innovative drugs to patients with confidence. www.qima-lifesciences.com

About CDT Equity Inc.

CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT’s future results of operations and financial position, CDT’s business strategy, prospective product candidates, product approvals, research and development cost timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT’s control, you should not rely on these forward-looking statements as predictions of future events.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.

Investors
CDT Equity Inc.
Info@cdtequity.com

__________________________
¹ https://onlinelibrary.wiley.com/doi/full/10.1002/ski2.317
² https://www1.hkexnews.hk/app/sehk/2026/108643/documents/sehk26061501863.pdf

Renk Group AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution

18. Sep 2026 / 12:20 CET/CEST, transmitted by GlobeNewswire.

The issuer is solely responsible for the content of this announcement.

---

Notification of Major Holdings

1. Details of issuer

2. Reason for notification

3. Details of person subject to the notification obligation

Legal entity

4. Name(s) of shareholder(s) holding directly 3% or more voting rights, if different from details of person subject to the notification obligation

5. Date on which threshold was crossed or reached

6. Total positions

7. Details on total positions

a. Voting rights attached to shares (Sec. 33, 34 WpHG)

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

8. Information in relation to the person subject to the notification obligation

9. In case of proxy voting according to Sec. 34 (3) WpHG

Date of general meeting

Total positions (6.) after general meeting:

10. Other useful information

Date

End of message

---

GlobeNewsWire Distribution Services include regulatory announcements, financial/corporate news and press releases.

Archive at www.globenewswire.com

---